BTIG raised the firm’s price target on Insulet (PODD) to $310 from $300 and keeps a Buy rating on the shares after its Q4 earnings beat. The ...

Investing.com -- BTIG upgraded Snowflake Inc (NYSE:SNOW) to "Buy" from "Neutral" and introduced a $220 price target on improving demand trends and potential AI-driven growth. The brokerage noted ...

When we spoke three years ago, your research was focused on the shopping center, net lease and health care subsectors. Is there anything new or different about your coverage universe here in 2025? Mr.

BTIG analyst Marie Thibault raised the firm’s price target on iRhythm (IRTC) to $135 from $120 and keeps a Buy rating on the shares after its ...

As of December 23, 2024, the average one-year price target for ImmunityBio is $14.54/share. The forecasts range from a low of $4.80 to a high of $31.50. The average price target represents an ...

For more information about the conference, email uscorporateaccess@btig.com. Please note that participants must be pre-registered to attend. To access BTIG insights, contact a BTIG ...

January 28, 2025--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the BTIG Annual ...

In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Zealand Pharma (ZLDPF – Research Report), with a price ...